Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.50 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.50 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.50 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.50 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.50 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.44 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.44 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | FDPS | P14324 | 1/20 | 0.49 |
| ▸ | PTPRA | P18433 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL136776 | 0.98 | GRIN2D (0.52) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Iodide SCHEMBL9693917 | 0.96 | GRIN2D (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Bromide SCHEMBL6484310 | 0.96 | APP (0.54) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL9466518 | 0.94 | APP (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL5249711 | 0.94 | APP (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Iodide SCHEMBL18110427 | 0.77 | HRH1 (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL9814518 | 0.77 | CYP2C9 (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL1739222 | 0.77 | HIF1A (0.48) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Bromide SCHEMBL10446668 | 0.76 | MAPK14 (0.40) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Bromide SCHEMBL15635739 | 0.75 | HIF1A (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976388-A1 | ANTIMICROBIAL SOLUTION COMPRISING A METALLIC SALT AND A SURFACTANT | CTT GROUP INC. (CA) | 2008-10-08 | — | — | EP | claimed |
| US-20080199502-A1 | Antimicrobial Solution Comprising a Metallic Salt and a Surfactant | CTT GROUP INC. (CA) | 2008-08-21 | — | — | US | claimed |
| WO-2006105669-A1 | ANTIMICROBIAL SOLUTION COMPRISING A METALLIC SALT AND A SURFACTANT | CTT GROUP INC. (CA) | 2006-10-12 | — | — | WO | claimed |
| US-6248161-B1 | Preparation of permanent color inks from water-soluble colorants using specific phosphonium salts | HEWLETT-PACKARD COMPANY | 2001-06-19 | — | — | US | claimed |
| US-11939427-B2 | Process for preparing polycarbonate and catalytic system used | ENI S.P.A. (IT) | 2024-03-26 | — | — | US | disclosed |
| EP-3710510-B1 | PROCESS FOR PREPARING POLYCARBONATE AND CATALYTIC SYSTEM USED | ENI SPA (IT) | 2021-09-22 | — | — | EP | disclosed |
| US-20210148567-A1 | Organic Colorant Complexes from Reactive Dyes and Articles Containing the Same | MILLIKEN & COMPANY (US) | 2021-05-20 | — | — | US | disclosed |
| US-20200369828-A1 | PROCESS FOR PREPARING POLYCARBONTE AND CATALYTIC SYSTEM USED | ENI S.P.A. (IT) | 2020-11-26 | — | — | US | disclosed |
| EP-3710510-A1 | PROCESS FOR PREPARING POLYCARBONATE AND CATALYTIC SYSTEM USED | ENI S.p.A. (IT) | 2020-09-23 | — | — | EP | disclosed |
| US-10689801-B2 | Colored coatings and artificial leathers containing colorant complexes | Millikan & Company (US) | 2020-06-23 | — | — | US | disclosed |
| US-10612190-B2 | Colored coatings and artificial leathers | MILLIKEN & COMPANY (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190153667-A1 | Colored Coatings and Artificial Leathers | MILLIKEN & COMPANY (US) | 2019-05-23 | — | — | US | disclosed |
| WO-2002062290-A2 | HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-15 | — | — | WO | disclosed |
| US-20020099208-A1 | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-25 | — | — | US | disclosed |
| CN-1066148-C | Tricyclic benzazepine compounds | MEIJI SEIKA CO (JP) | 2001-05-23 | — | — | CN | disclosed |
| US-6194441-B1 | GRAMNEGATIVE AND GRAMPOSITIVE BACTERIA | ZENECA LTD. (GB) | 2001-02-27 | — | — | US | disclosed |
| US-6093714-A | AN ANTIALLERGENS FOR TREATMENT AND PREVENTION OF BRONCHIAL ASTHMA, ECZEMA, HIVES, ALLERGIC GASTROINTESTINAL TROUBLES, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS | MEIJI SEIKA KAISHA, LTD. (JP) | 2000-07-25 | — | — | US | disclosed |
| EP-1020498-A1 | Preparation of permanent color inks from water-soluble colorants using specific phosphonium salts | Hewlett-Packard Company (US) | 2000-07-19 | — | — | EP | disclosed |
| CN-1190971-A | Tricyclic benzazepine * compounds | MEIJI SEIKA CO (JP) | 1998-08-19 | — | — | CN | disclosed |
| EP-0834512-A1 | TRICYCLIC BENZAZEPINE COMPOUNDS | MEIJI SEIKA KAISHA LTD. (JP) | 1998-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099208-A1 | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | MAVS, ZC3HAV1, EIF2AK2 | GRIN2D 3799/4885GRIN3B 3174/4885GRIN1 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.